Hormone receptor positive breast cancer+1
Not recruitingStudy to Improve Tolerance of Sacituzumab Govitecan with Loperamide and Filgrastim in Patients with Advanced Triple-Negative or Luminal Breast Cancer
Study to Improve Tolerance of Sacituzumab Govitecan with Loperamide and Filgrastim in Patients with Advanced Triple-Negative or Luminal Breast Cancer
- Disease:Hormone receptor positive breast cancerTriple negative breast cancer
- Substances:FilgrastimLoperamide Hydrochloride+1
Spain- Participants:18–64 years · 65+ years
- Substances:Filgrastim
- Sponsor:Medica Scientia Innovation Research S.L.








